Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (SIR-POSA)

C

Ciceri Fabio

Status and phase

Completed
Phase 2

Conditions

Fungal Infection
Graft Vs Host Disease
Transplant-Related Hematologic Malignancy
Leukemia, Acute
Myelodysplastic Syndromes

Treatments

Drug: Conditioning treatment "Thiotepa-Treosulfan-Fludarabine"
Drug: GvHD prophylaxis
Procedure: PBSC graft
Drug: Primary antifungal prophylaxis

Study type

Interventional

Funder types

Other

Identifiers

NCT03434704
2017-004423-78

Details and patient eligibility

About

SIR-POSA is a phase II trial of peripheral blood stem cell (PBSC) transplantation from a partially compatible family (Haplo) donor in patients with a blood tumor (myelodysplastic syndrome (MDS) and acute leukemia) treated for the prevention of primary fungal infections with posaconazole. The aim is evaluate the composite end-point graft-versus-host disease-free, relapse-free survival (GRFS) in these patients and evaluate the feasibility and efficacy of posaconazole oral tablets as primary antifungal prophylaxis.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of myelodysplastic syndromes or acute leukemia
  • Activation of an alternative donor search by the Italian Bone Marrow Donor Registry (IBMDR) with absence of a 10/10 Human Leukocyte Antigens (HLA) matched unrelated donor
  • Age >18
  • Unavailability of a HLA-matched related donor (MRD)
  • Performance status : Eastern Cooperative Oncology Group (ECOG) <3
  • Written and signed informed consent
  • Life expectancy not severely limited by concomitant illness.

Exclusion criteria

  • Women of child-bearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective method of birth control such as condoms, implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), vasectomised partner on treatment and for at least 6 months thereafter.
  • Pregnant or nursing (lactating) women.
  • Known allergies, hypersensitivity, or intolerance to any experimental drugs.
  • Any active, uncontrolled infection.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Single Arm Treatment
Experimental group
Description:
Conditioning treatment "Thiotepa-Treosulfan-Fludarabine"; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis.
Treatment:
Drug: Primary antifungal prophylaxis
Procedure: PBSC graft
Drug: GvHD prophylaxis
Drug: Conditioning treatment "Thiotepa-Treosulfan-Fludarabine"

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems